Drug Profile
Research programme: islet stem cell therapy - Sanofi/ViaCell
Latest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital
- Developer Sanofi
- Class Cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 16 Nov 2007 ViaCell has been acquired by PerkinElmer
- 30 Mar 2005 Preclinical trials in Diabetes mellitus in USA (unspecified route)